FDA’s Orphan Exclusivity Requirement For “Clinical Superiority” Challenged In Court
This article was originally published in The Pink Sheet Daily
Executive Summary
Depomed argues in a suit against FDA that it should not have to show Gralise (gabapentin) is clinically superior to Neurontin since Neurontin never received an orphan drug designation or orphan exclusivity.
You may also be interested in...
FDA Grants Gralise Orphan Exclusivity But Rejects Policy Change
FDA bows to a court ruling requiring it to award orphan drug market exclusivity to Depomed’s gabapentin, but the agency says it will continue to require the sponsor of a drug that is the “same” as a previously approved drug to show that it is “clinically superior” in order to be eligible.
FDA May Modify Orphan Exclusivity Reg, But Label Carve-Out Policy Is Intact
A district court rejects FDA’s “clinical superiority” requirement for Gralise orphan exclusivity, while another court upholds the agency’s finding that an ANDA label carve-out may overlap partially with a protected method of use.
Plausibility Takes A Hit: FDA Revokes Orphan Exclusivity For Octapharma’s Wilate
In the first-ever rescission of marketing exclusivity for an orphan drug, FDA concludes that data does not show Wilate is superior to CSL Behring’s Factor VIII drug Humate-P. Wilate had previously been awarded orphan drug exclusivity for the same indication because of a “plausible hypothesis” that it was safer.